Table 4. Univariate and Multivariable analysis of overall survival in 187 patients with renal cell carcinoma.
| Variable | Univariate | Multivariable | ||
|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Age (y), <60 vs. ≥60 | 1.004 (0.956–1.054) | 0.875 | - | - |
| Sex, male vs. female | 1.800 (0.617–5.251) | 0.276 | - | - |
| Thrombocytosis, no vs. yes | 3.956 (1.237–12.656) | 0.012 | 2.428 (0.586–10.063) | 0.221 |
| Histology, conventional vs. nonconventional | 0.442 (0.058–3.384) | 0.419 | - | - |
| T stage, T1+T2 vs. T3+T4 | 5.149 (1.722–15.399) | 0.001 | 2.153 (0.508–9.116) | 0.298 |
| Grade, G1+G2 vs. G3+G4 | 1.457 (0.503–4.223) | 0.486 | - | - |
| Tumor size (cm), <7 vs. ≥7 | 3.839 (1.328–11.102) | 0.008 | 2.104 (0.598–7.410) | 0.247 |
| Distant metastasis, no vs. yes | 5.098 (1.779–14.607) | 0.001 | 6.522 (2.094–20.308) | 0.001 |
| NLR, <1.81 vs. ≥1.81 | 2.202 (0.689–7.035) | 0.172 | - | - |
| PLR, <128.7 vs. ≥128.7 | 3.076 (0.855–11.073) | 0.070 | - | - |
HR, hazard ratio; CI, confidence interval; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio.